Stephanie Casey Parks
Senior Principal Scientist Amgen
Stephanie Casey Parks, PhD is a Senior Principal Scientist and group leader in Oncology Research at Amgen. She leads in vivo preclinical research efforts across diverse therapeutic modalities, including small and large molecules, antibody-drug conjugates, and T cell engagers. She studies in vivo biology of emerging targets, characterizes pharmacodynamic and efficacy responses to new molecules, and creates novel models. She obtained a B.S. in Microbiology, Immunology, and Molecular Genetics from UCLA and a PhD in cancer biology from UC Irvine. She performed postdoctoral work at Stanford, where she studied the interplay between oncogenes and the anti-tumor immune response using GEMMs.
Seminars
Wednesday 28th January 2026
Showcasing Model Selection Case Studies to Highlight Strategic Preclinical Decision-Making
8:30 am
- Presenting humanized and knock-in preclinical models to solve distinct research challenges and achieve relevant pharmacodynamic and efficacy insights
- Discussing model selection rationale and how to tailor the model to the underlying biology
- Sharing lessons learned to inform broader preclinical strategies and guide model selection across diverse therapeutic programs
Wednesday 28th January 2026
Fireside Chat: Exploring the Utility of GEMM Models to Balance Translational Insights & Practical Limitations
9:30 am
- Leveraging Genetically Engineered Mouse Models (GEMMs) to replicate complex genetic drivers of oncogenesis and provide a more physiologically relevant tumor microenvironment for therapeutic evaluation
- Navigating challenges of cost, breeding complexity, and experimental timelines to evaluate feasibility and scalability across diverse oncology research programs
- Comparing translational predictability of GEMMs vs syngeneic, PDX, and humanized models in preclinical oncology research
